Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
The “CellSerach” system is widely used to detect circulating tumor cells (CTCs), but tumor cells undergoing epithelial-mesenchymal transition (EMT) may not be captured with the “CellSearch” because an antibody against EpCAM, an antigen expressing on epithelial cells, is used to capture CTCs. Accordingly, we employed a novel microfluidic device (“CTC-chip”) in which any antibody to capture CTCs is easily conjugated, and evaluated the efficiency in capturing CTCs in experimental studies. The “CTC-chip” provided similar efficiency to “CellSeach” in capturing PC-9 cells with EpCAM expression. In capturing MESO-4 cells without EpCAM expression, the “CTC-chip” conjugated with an anti-podoplanin antibody provided a high efficiency (55-70%) whereas MESO-4 cells were not captured with the “CellSearch”.
|